Kinase Inhibitors

Our multifaceted support strategy

Kinase inhibitors, or compounds that block the activity of one or more kinase enzymes, have shown significant promise in the treatment of cancer and other diseases. Currently, 80 small molecule protein kinase inhibitors have been approved by the FDA, demonstrating their clinical utility and therapeutic potential. In addition to the discovery of more selective or potent inhibitors, researchers are seeking to develop covalent kinase inhibitors, targeted kinase degraders, and other next-generation modalities.

Our services can support the discovery and development of kinase-inhibiting therapeutics by providing unmatched insight into the cellular landscape via proteomic and chemoproteomic profiling. In addition to high-throughput non-covalent and covalent screening, we can provide extensive and sophisticated follow-up services to optimize therapeutic leads and characterize treatment efficacy.

Leverage kinome profiling technology purpose-built for kinase inhibitor development
Screening approaches can identify non-covalent and covalent leads, as well as promising compounds for degrader development
Comprehensive proteomic and chemoproteomic profiling techniques provide valuable information for preclinical development

How we can help

KinomeScout™
Our kinome profiling technology enables the label-free identification and quantification of kinases, including many understudied 'dark kinases' with therapeutic potential.
SignalingScout™
By profiling the phosphoproteome, researchers can characterize downstream effects of gene therapies to evaluate treatment efficacy and elucidate disease mechanisms.

Explore Other Modalities

We offer support for the development of a broad range of therapeutic modalities.

ADCs
Targeted immunotherapeutics for cancer treatment and beyond
Gene Therapies
Modify genetic content and expression to enable new frontiers of disease treatment
Cell Therapies
Harness the power of cell therapy to overcome unmet disease challenges
Radiotherapeutics
Harness the ultra-sensitive analytic power of ICP-MS for radioligand discovery and development
Molecular Glues
Induce or stabilize protein-protein interactions for therapeutic applications
Targeted Degraders
Induce target degradation with precision and potency
Covalent Drugs
Unlock potent and selective therapeutics through covalent binding
DNA- and RNA-Targeting Drugs
Accelerate the development of DNA- and RNA-targeted small-molecule therapeutics
Oligonucleotide Therapeutics
Modulate protein expression and splicing with RNA-binding ASOs and RNAi